Napsin A Positive: Meaning in Lung Cancer Diagnosis

A positive Napsin A result on a tissue biopsy strongly suggests that the tumor is a lung adenocarcinoma, the most common type of lung cancer. Napsin A is a protein that pathologists look for using a staining technique on biopsy samples, and finding it in tumor cells is one of the most reliable signals that a cancer started in the lung and has glandular (adenocarcinoma) features. The story is a bit more nuanced than that, though, because Napsin A can occasionally appear in cancers from other organs, its absence does not rule out lung adenocarcinoma, and the result carries implications beyond just naming the tumor type.

What Napsin A Actually Is

Napsin A is an enzyme, specifically an aspartic protease, that is naturally produced in two places in the body: the lungs and the kidneys. In the lungs, it lives inside type II pneumocytes, the cells lining the air sacs that produce surfactant, the slippery substance that keeps your lungs from collapsing with each breath. Napsin A helps process surfactant protein B, one of the key ingredients of that surfactant mixture.¹ In the kidneys, it shows up in cells of both the cortex and medulla, with stronger staining in the proximal tubules.²

The reason this matters for cancer diagnosis is straightforward: when a cell turns cancerous, it often keeps making the proteins it made before it went rogue. A lung adenocarcinoma cell, which descends from those surfactant-producing pneumocytes, tends to keep churning out Napsin A. So when a pathologist finds Napsin A in a tumor, it points back toward a lung origin. The protein was first linked to lung adenocarcinoma when researchers discovered that a pair of proteins found in over 90% of primary lung adenocarcinomas turned out to be identical to Napsin A.³

How Pathologists Use Napsin A in Practice

When a lung biopsy comes into the lab, the pathologist needs to answer two urgent questions: Is this cancer? And if so, what kind? The distinction between adenocarcinoma and squamous cell carcinoma, the two most common forms of non-small cell lung cancer, drives treatment decisions. Certain targeted therapies and chemotherapy regimens work for one type but not the other, so getting the subtype right is not academic; it changes what drugs you receive.

Napsin A is one of the strongest markers for adenocarcinoma. In large studies, roughly 85 to 90% of lung adenocarcinomas stain positive for it.⁴ Squamous cell carcinomas, by contrast, are essentially always negative. One study of 198 adenocarcinomas and 79 squamous cell carcinomas found Napsin A positivity in about 86% of the adenocarcinomas and zero percent of the squamous tumors.⁵ That near-perfect specificity for one subtype over the other makes the marker extremely useful.

Napsin A is also more sensitive than TTF-1, the other major lung adenocarcinoma marker, in head-to-head comparisons. In one large evaluation of over 1,600 cases, Napsin A picked up 87% of lung adenocarcinomas while TTF-1 caught only 64%.⁴ The two markers catch somewhat different subsets of tumors, which is why labs almost always run both.

The TTF-1 and Napsin A Combination

Rather than relying on a single stain, most pathology laboratories use Napsin A alongside TTF-1 as a pair. The logic is simple: some adenocarcinomas lose Napsin A expression, and a different subset loses TTF-1, but only a small fraction loses both. When both markers light up in a tumor, the diagnosis of primary lung adenocarcinoma is about as solid as it gets.

In one study of 120 primary lung adenocarcinomas, about 79% were positive for both Napsin A and TTF-1. Another 8% were Napsin A positive but TTF-1 negative, and about 3% showed the reverse pattern. Only around 9% were negative for both.⁶ A meta-analysis pooling data from ten studies found that the combined test had a sensitivity of 76% and a specificity that essentially hit 100% for distinguishing lung adenocarcinoma from squamous cell carcinoma.⁷

That specificity number is the critical one. When both markers are positive, the chance of a squamous cell carcinoma being misclassified as an adenocarcinoma is vanishingly small. The sensitivity is lower because some adenocarcinomas genuinely lose expression of both markers, particularly poorly differentiated ones, but the payoff in diagnostic confidence when the stains are positive is enormous.

Telling Primary Lung Cancer Apart from Metastases

One of the trickier problems in pathology is figuring out whether a tumor found in the lung actually started there or spread from somewhere else. Cancers from the colon, breast, kidney, and many other sites can metastasize to the lungs, and under the microscope these metastases sometimes look a lot like a primary lung cancer. This is where Napsin A earns some of its greatest diagnostic value.

In one study, over 90% of primary lung adenocarcinomas stained positive for Napsin A, while metastatic adenocarcinomas in the lung from other organs and mesotheliomas were all completely negative.⁸ That result lines up with the biology: if a colon cancer spreads to the lung, it does not suddenly start making lung-specific proteins. It still looks and acts like a colon cancer at the molecular level.

Combining Napsin A with TTF-1 makes this distinction even sharper. If a lung mass is double-positive for both markers, the odds overwhelmingly favor a primary lung adenocarcinoma rather than a metastasis from the breast, colon, pancreas, or most other sites.⁶

Where Napsin A Can Be Misleading

Napsin A is not exclusive to lung cancer. Because the protein is also made normally in the kidney, certain kidney cancers retain its expression. Papillary renal cell carcinoma is the biggest culprit, with roughly 40 to 79% of cases staining positive depending on the study.⁹ Clear cell renal cell carcinoma shows positivity in roughly a third of cases, and a broader range of renal tumors can express it at lower rates.¹⁰

This overlap matters most when pathologists encounter a metastatic carcinoma of unknown primary that happens to be Napsin A positive. In that scenario, both lung and kidney need to stay on the differential diagnosis. TTF-1 helps here because kidney cancers are almost always TTF-1 negative, so a tumor that is positive for both markers still points strongly toward the lung.

Ovarian clear cell carcinoma is another important cross-reactor. About 72% of these tumors express Napsin A, and endometrial clear cell carcinomas do so roughly 43% of the time.⁵ Papillary thyroid carcinoma can occasionally stain positive too, though at much lower rates. The takeaway is that a positive Napsin A result always needs to be interpreted in context, considering the patient’s clinical picture, imaging findings, and the results of other stains. It is never a one-marker diagnosis.

There is also a technical false-positive pitfall. Normal lung tissue that gets trapped between cancer cells can include Napsin A-positive pneumocytes or alveolar macrophages, and an unwary reader of the slide might mistake that background staining for tumor positivity. This has been flagged as a possible explanation for rare reports of squamous cell carcinomas appearing to be Napsin A positive.¹¹

Poorly Differentiated Tumors and Difficult Biopsies

The cases that give pathologists the most trouble are poorly differentiated tumors: cancers that have lost so much of their normal architecture that they do not obviously look like either adenocarcinoma or squamous cell carcinoma under the microscope. These are also the cases where small biopsy specimens, sometimes just a needle core or a few cells from a fine-needle aspiration, make visual classification nearly impossible. Napsin A becomes especially important here.

In poorly differentiated non-small cell lung cancers, Napsin A still picks up the adenocarcinoma signal in a majority of cases. One study found that Napsin A correctly identified adenocarcinoma in these difficult tumors with about 89% sensitivity and 97% specificity.¹² Another study focused on poorly differentiated areas found TTF-1 positive in only 53% of adenocarcinomas while Napsin A caught 69%, again demonstrating its complementary value.¹³

For small biopsies, labs have developed cocktail stains that combine Napsin A with p40, a squamous cell marker, on the same slide. Using this approach, the Napsin A positive/p40 negative pattern identified adenocarcinoma with 94% sensitivity and 100% specificity, while the reverse pattern (Napsin A negative/p40 positive) flagged squamous cell carcinoma with 100% sensitivity and specificity.¹⁴ These cocktails save precious tissue, which matters because the same biopsy material may also be needed for molecular testing.

Napsin A and Neuroendocrine Lung Tumors

Lung cancers are not all non-small cell. Small cell lung cancer and other neuroendocrine tumors, including carcinoid tumors and large cell neuroendocrine carcinoma, make up a distinct category with very different biology and treatment. Napsin A turns out to be a useful negative marker here: small cell carcinomas and carcinoid tumors are consistently negative for it. In one study of 36 small cell carcinomas, every single one was Napsin A negative, while TTF-1 was positive in 97% of them.¹⁵

This discordance between TTF-1 and Napsin A is diagnostically powerful. TTF-1 positivity in a lung tumor does not tell you whether you are dealing with an adenocarcinoma or a small cell carcinoma, since both frequently express it. But if the tumor is also Napsin A positive, small cell carcinoma is essentially off the table. If TTF-1 is positive and Napsin A is negative, small cell carcinoma or another neuroendocrine tumor becomes a serious consideration.

Large cell neuroendocrine carcinoma presents a wrinkle. About 15% of these tumors express Napsin A, though the staining is typically focal and weak, unlike the diffuse strong staining seen in adenocarcinomas.¹⁶ These Napsin A-positive large cell neuroendocrine tumors may represent a biologically distinct subset with adenocarcinoma-like features, and their identification could eventually influence treatment strategies.

What Napsin A Tells You About Prognosis

Beyond diagnosis, Napsin A status carries prognostic information. In surgically resected lung adenocarcinomas, the absence of Napsin A expression has been identified as an independent predictor of shorter survival.¹⁷ Multiple groups have confirmed this finding and recommended that Napsin A staining be performed routinely in postoperative lung adenocarcinoma patients to help estimate prognosis.¹⁸

The association extends to advanced disease. A recent study of patients with lung cancer that had spread to the spine found that those whose tumors expressed Napsin A had a median overall survival of about 5.4 years, compared with roughly 1.4 years for Napsin A-negative patients. After spinal metastasis specifically, Napsin A-positive patients survived a median of 2.3 years versus 0.7 years for negative patients. The Napsin A-positive group also had better neurological function after surgery.¹⁹

The likely explanation is that Napsin A expression reflects tumor differentiation. Well-differentiated adenocarcinomas, which retain more features of normal lung tissue, tend to express Napsin A at higher levels. These tumors generally behave less aggressively. Poorly differentiated tumors that have lost Napsin A expression have drifted further from their tissue of origin and often carry a worse prognosis. Earlier research established this connection: Napsin A expression was associated with a high degree of tumor differentiation in lung adenocarcinoma.²⁰

Connections to Molecular Testing and Targeted Therapy

In modern lung cancer treatment, identifying the specific molecular mutations driving the cancer is often more important than the histological subtype alone. The most consequential of these is the EGFR mutation, because patients whose tumors carry it can receive highly effective targeted drugs. Napsin A status turns out to have a practical connection to this molecular testing.

In one study, all lung adenocarcinomas that were negative for both TTF-1 and Napsin A also turned out to lack EGFR mutations. None of the double-negative tumors harbored the mutation.²¹ This finding has a direct practical use: when biopsy tissue is limited, which it frequently is, knowing that a double-negative tumor is extremely unlikely to carry an EGFR mutation means the lab can skip EGFR testing and use that precious tissue for other molecular assays instead.

There is also early laboratory evidence that Napsin A may play a role in drug resistance. In cell line experiments, overexpressing Napsin A in lung cancer cells that had become resistant to gefitinib (an EGFR-targeted drug) restored their sensitivity to the medication. The mechanism appeared to involve reversing a process called epithelial-to-mesenchymal transition, which is how cancer cells become more mobile and treatment-resistant.²² This is still preclinical work, not something that changes treatment today, but it hints that Napsin A may be more than a passive marker and could have functional relevance in how tumors respond to therapy.

Napsin A in Pleural Fluid and Other Non-Tissue Specimens

Lung cancer frequently causes fluid to accumulate around the lungs, called a pleural effusion. Draining this fluid and examining the cells in it is a less invasive way to diagnose the cancer than a tissue biopsy, but it can be harder for pathologists to work with because the cells are scattered rather than organized in tissue architecture. Napsin A and TTF-1 can be applied to cell block preparations from these fluid samples.

In a study of 80 pleural effusions, the combination of TTF-1 and Napsin A staining on cell blocks was positive in 80% of lung adenocarcinomas. For the remaining double-negative cases, measuring Napsin A protein levels in the fluid itself identified an additional third of the missed cancers, with 100% specificity.²³ This means the marker has value not just on solid tissue but in the fluid-based diagnostic settings that are increasingly common in clinical practice.

Monoclonal Versus Polyclonal Antibodies

Not all Napsin A stains perform identically. The antibodies used to detect the protein come in two varieties: monoclonal, which target a single precise spot on the protein, and polyclonal, which recognize multiple spots. The choice matters for accuracy. A comparison study found that polyclonal Napsin A stained 27 out of 91 non-lung carcinomas across eight different organ sites, while monoclonal Napsin A stained only 12 out of 100 non-lung carcinomas across four sites.²⁴ In other words, the monoclonal version is more specific, giving fewer false positives in non-lung tumors. Most modern laboratories have moved to monoclonal antibodies for this reason.

The sensitivity difference between the two is small, with the polyclonal version picking up a few more true lung cancers (81% versus 76% in that study). But the tradeoff of catching a handful of extra true positives while substantially increasing false positives is generally not worth it, especially since TTF-1 can catch most of the cases that monoclonal Napsin A misses.

Tissue-Conserving Multiplex Stains

Small biopsies and fine-needle aspirations yield very little tissue, and modern lung cancer workups demand answers to many questions from that small sample: subtype, molecular mutations, PD-L1 expression for immunotherapy decisions. Every slide used for one stain is tissue that cannot be used for another. This pressure has driven the development of multiplex staining approaches that combine several markers on a single slide.

Dual-color stains pairing TTF-1 with Napsin A (for adenocarcinoma) and p63 with CK5 (for squamous cell carcinoma) allow pathologists to classify the tumor using just two slides instead of four.²⁵ Even more advanced approaches have combined all four antibodies onto a single section using four different color chromogens, capable of identifying adenocarcinoma, squamous cell carcinoma, and even combined tumors that have features of both.²⁶ These techniques are gradually entering routine practice, and Napsin A is a core component of all of them.